MetaCap

Lexicon Pharmaceuticals (LXRX) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexicon Pharmaceuticals (LXRX) has outperformed Olema Oncology (OLMA) over the past year, gaining 14.2% versus a loss of 69.7%. Over five years, OLMA leads with a -66.4% price change compared with -67.7% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $615.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LXRX+14.18%OLMA-69.70%
+105%+12%-81%
Nov 21, 20251 yearNov 20, 2026
LXRX-69.15%OLMA-69.16%
+52%-24%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LXRX versus OLMA key metrics
MetricLXRXOLMA
Share price$1.53$7.02
Market cap$681.21M$615.00M
1-day change-8.38%-1.82%
YTD return+33.04%-71.92%
1-year return+14.18%-69.70%
5-year return-67.72%-66.36%
EPS (TTM)$-0.15$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$49.80M—
Revenue growth (YoY)+60.24%—
Net income (latest FY)$-50.34M$-162.45M
Gross margin99.45%—
Operating margin-98.21%—
Net margin-101.08%—
52-week high$2.68$36.26
52-week low$1.10$6.24
Distance from 52-week high-42.91%-80.64%
Analyst consensusbuystrong_buy
Avg. price target upside+195.42%+405.70%
Average volume2.56M1.27M
Shares outstanding445.23M87.61M
Employees81131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LXRX has outperformed OLMA by 83.9 percentage points over the past year.

About Lexicon Pharmaceuticals

LXRX stock →

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

LXRX vs OLMA FAQ

Which is bigger, Lexicon Pharmaceuticals or Olema Oncology?

Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $615.00M for Olema Oncology (OLMA).

Which stock has performed better over the past year, LXRX or OLMA?

LXRX returned +14.18% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.

Are Lexicon Pharmaceuticals and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons